1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Vaccarella S, Lortet-Tieulent J, Plummer
M, Franceschi S and Bray F: Worldwide trends in cervical cancer
incidence: Impact of screening against changes in disease risk
factors. Eur J Cancer. 49:3262–3273. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Meijer CJ and Snijders PJ: Cervical cancer
in 2013: Screening comes of age and treatment progress continues.
Nat Rev Clin Oncol. 11:77–78. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Castle PE: Gynaecological cancer: New
standard of care-HPV testing for cervical cancer screening. Nat Rev
Clin Oncol. 12:194–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Tago K, Nakamura T, Nishita M, Hyodo J,
Nagai S, Murata Y, Adachi S, Ohwada S, Morishita Y, Shibuya H, et
al: Inhibition of Wnt signaling by ICAT, a novel
beta-catenin-interacting protein. Genes Dev. 14:1741–1749.
2000.PubMed/NCBI
|
7
|
Daniels DL and Weis WI: ICAT inhibits
beta-catenin binding to Tcf/Lef-family transcription factors and
the general coactivator p300 using independent structural modules.
Mol Cell. 10:573–584. 2002. View Article : Google Scholar : PubMed/NCBI
|
8
|
Graham TA, Clements WK, Kimelman D and Xu
W: The crystal structure of the beta-catenin/ICAT complex reveals
the inhibitory mechanism of ICAT. Mol Cell. 10:563–571. 2002.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Koyama T, Tago K, Nakamura T, Ohwada S,
Morishita Y, Yokota J and Akiyama T: Mutation and expression of the
beta-catenin-interacting protein ICAT in human colorectal tumors.
Jpn J Clin Oncol. 32:358–362. 2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Choi HJ, Huber AH and Weis WI:
Thermodynamics of beta-catenin-ligand interactions: The roles of
the N- and C-terminal tails in modulating binding affinity. J Biol
Chem. 281:1027–1038. 2006. View Article : Google Scholar : PubMed/NCBI
|
11
|
Gottardi CJ and Gumbiner BM: Role for ICAT
in beta-catenin-dependent nuclear signaling and cadherin functions.
Am J Physiol Cell Physiol. 286:C747–C756. 2004. View Article : Google Scholar : PubMed/NCBI
|
12
|
Thompson EW, Newgreen DF and Tarin D:
Carcinoma invasion and metastasis: A role for
epithelial-mesenchymal transition? Cancer Res. 65:5991–5995;
discussion 5995. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
An HT, Yoo S and Ko J: α-Actinin-4 induces
the epithelial-to-mesenchymal transition and tumorigenesis via
regulation of Snail expression and β-catenin stabilization in
cervical cancer. Oncogene. 35:5893–5904. 2016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Li Q, Bao W, Fan Q, Shi WJ, Li ZN, Xu Y
and Wu D: Epidermal growth factor receptor kinase substrate 8
promotes the metastasis of cervical cancer via the
epithelial-mesenchymal transition. Mol Med Rep. 14:3220–3228. 2016.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Sun R, Jiang B, Qi H, Zhang X, Yang J,
Duan J, Li Y and Li G: SOX4 contributes to the progression of
cervical cancer and the resistance to the chemotherapeutic drug
through ABCG2. Cell Death Dis. 6:e19902015. View Article : Google Scholar : PubMed/NCBI
|
18
|
He X, Qian Y, Cai H, Yang S, Cai J and
Wang Z: RhoC is essential in TGF-β1 induced epithelial-mesenchymal
transition in cervical cancer cells. Oncol Lett. 10:985–989.
2015.PubMed/NCBI
|
19
|
Zhang J, Zhu D, Lv Q, Yi Y, Li F and Zhang
W: The key role of astrocyte elevated gene-1 in CCR6-induced EMT in
cervical cancer. Tumour Biol. 36:9763–9767. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Koay MH, Crook M and Stewart CJ: Cyclin
D1, E-cadherin and beta-catenin expression in FIGO stage IA
cervical squamous carcinoma: Diagnostic value and evidence for
epithelial-mesenchymal transition. Histopathology. 61:1125–1133.
2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ye GD, Sun GB, Jiao P, Chen C, Liu QF,
Huang XL, Zhang R, Cai WY, Li SN, Wu JF, et al: OVOL2, an inhibitor
of WNT signaling, reduces invasive activities of human and mouse
cancer cells and is down-regulated in human colorectal tumors.
Gastroenterology. 150:659–671.e616. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Li Y, Jin K, van Pelt GW, van Dam H, Yu X,
Mesker WE, Ten Dijke P, Zhou F and Zhang L: c-Myb enhances breast
cancer invasion and metastasis through the Wnt/beta-catenin/Axin2
pathway. Cancer Res. 76:3364–3375. 2016. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ma F, Ye H, He HH, Gerrin SJ, Chen S,
Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, et al: SOX9 drives
WNT pathway activation in prostate cancer. J Clin Invest.
126:1745–1758. 2016. View
Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang K, Zhang J, Han L, Pu P and Kang C:
Wnt/beta-catenin signaling in glioma. J Neuroimmune Pharmacol.
7:740–749. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Sekiya T, Nakamura T, Kazuki Y, Oshimura
M, Kohu K, Tago K, Ohwada S and Akiyama T: Overexpression of Icat
induces G2 arrest and cell death in tumor cell mutants
for adenomatous polyposis coli, beta-catenin, or Axin. Cancer Res.
62:3322–3326. 2002.PubMed/NCBI
|
26
|
Zhang K, Zhu S, Liu Y, Dong X, Shi Z,
Zhang A, Liu C, Chen L, Wei J, Pu P, et al: ICAT inhibits
glioblastoma cell proliferation by suppressing Wnt/β-catenin
activity. Cancer Lett. 357:404–411. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Shi Z, Qian X, Li L, Zhang J, Zhu S, Zhu
J, Chen L, Zhang K, Han L, Yu S, et al: Nuclear translocation of
beta-catenin is essential for glioma cell survival. Pharmacology.
7:892–903. 2012.
|
28
|
Ono M, Yin P, Navarro A, Moravek MB, Coon
JSV, Druschitz SA, Gottardi CJ and Bulun SE: Inhibition of
canonical WNT signaling attenuates human leiomyoma cell growth.
Fertil Steril. 101:1441–1449. 2014. View Article : Google Scholar : PubMed/NCBI
|
29
|
Domingues MJ, Rambow F, Job B, Papon L,
Liu W, Larue L and Bonaventure J: β-catenin inhibitor ICAT
modulates the invasive motility of melanoma cells. Cancer Res.
74:1983–1995. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Reifenberger J, Knobbe CB, Wolter M,
Blaschke B, Schulte KW, Pietsch T, Ruzicka T and Reifenberger G:
Molecular genetic analysis of malignant melanomas for aberrations
of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int
J Cancer. 100:549–556. 2002. View Article : Google Scholar : PubMed/NCBI
|
31
|
Zhang Y, Li T, Guo P, Kang J, Wei Q, Jia
X, Zhao W, Huai W, Qiu Y, Sun L, et al: MiR-424-5p reversed
epithelial-mesenchymal transition of anchorage-independent HCC
cells by directly targeting ICAT and suppressed HCC progression.
Sci Rep. 4:62482014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Jamora C and Fuchs E: Intercellular
adhesion, signalling and the cytoskeleton. Nat Cell Biol.
4:E101–E108. 2002. View Article : Google Scholar : PubMed/NCBI
|
33
|
Angadi PV, Patil PV, Angadi V, Mane D,
Shekar SS, Kale AD and Kardesai SG: Immunoexpression of epithelial
mesenchymal transition proteins E-cadherin, β-catenin, and
N-cadherin in oral squamous cell carcinoma. Int J Surg Pathol.
24:696–703. 2016. View Article : Google Scholar : PubMed/NCBI
|